Australasian Society for Infectious Diseases

Guidelines for use of antifungal agents in treatment of invasive fungal infection (Draft, July 2002)

REFERENCES

1. Espinel-Ingroff A.. In Vitro Fungicidal Activities of voriconzole, itraconazole and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Micro 2001, 39: 954-958
   
   
2. Butler WT, Bennett JE, Alling DW et al. Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med 1964; 61:175-87
   
   
3. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29:1402-7
   
   
4. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32:686-93
   
   
5. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30:662-78.
   
   
6. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus Clin Infect Dis 2000; 30:696-709.
   
   
7. Sobel JD for the Mycoses Study Group. Infectious Diseases Society of America. Practice guidelines for the treatment of fungal infections. Clin Infect Dis, 2000; 30:652
   
   
8. Wingard JR, White MH, Anaissie E et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000; 31:1155-63
   
   
9. White MH, Bowden RA, Sandler, ES et al. Randomised, double-blind clincial trial of Amphotericin B colloidal dispersion vs Amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis, 1998; 27:296-302
   
   
10. Bowden R, Chandraseker P, White MH et al. A double blind randomized controlled trial of amphotericin B colloidal dispersion versus amphotericin B for the treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35:359-66
    
    
11. Clemons KV, Stevens DA. Comparison of Fungizone, Amphotericin B colloidal dispersion, Liposomal amphotericin B and Amphotericin B lipid complex for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother 1998; 42:899-902
    
    
12. Clark AD, McKendrick S, Tansey PJ, Franklin IM, Chopra R. A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol 1998; 103:198-204
    
    
13. Pfaller MA, Diekema DJ, Jones RN et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program, J Clin Micro, 2001; 39:3254-9
    
    
14. Boogaerts M, Winston DJ, Bow EJ et al. Intravenous and oral itraconazole versus intravenous Amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy, Ann Intern Med 2001; 135; 412-422
    
    
15. Johnson LB, Kaufman CA. Voriconazole: A new triazole antifungal agent. Clinical Infectious Disease 2003;36:630-7
    
    
16. Espinel-Ingroff A. Comparison of in vitro activities of the new triazoles SCH56592 and echinocandins MK-0991 and LY 303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Micro 1998;36:2950-6
    
    
17. Petranyi G, Meingassner JG, Mieth H. Activity of terbinafine in experimental fungal infections of laboratory animals. Antimicrob Agents Chemother 1987; 31:1558-61.
    
    
18. Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol 2001; 39:91-5.
    
    
19. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14
    
    
20. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340:764-71.
    
    
21. Patterson TF, Kirkpatrick WR, White M et al Invasive Aspergillosis - Disease spectrum, treatment practices and outcomes. Medicine 2000; 79: 250-60.
    
    
22. Fleming RV, Kantarjian HM, Husni R et al. Comparison of Amphotericin B Lipid Complex (ABLC) vs liposomal amphotericin B in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001; 40: 511-20
    
    
23. Prentice HG, Hann IM, Herbrecht R et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997; 98:711-8.
    
    
24. Winston DJ, Hathorn JW, Schuster MG et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000; 108:282-9
    
    
25. Malik IA, Moid I, Aziz Z, et al. A randomised comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998; 6:478-83.
    
    
26. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. New Engl J Med, 2002, 346, 225-34.
    
    
27. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. Br Med J 2001; 322:579-82
    
    
28. Leenders ACAP, Daene S, Jansen RLH et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haem, 1998; 103,205-212.
    
    
29. Ellis M, Spence D, de Pauw B et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998, 27:1406-12.
    
    
30. Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-96.
    
    
31. Wingard JR, Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transpl, 1997; 19:343-347
    
    
32. Noskin G, Pietrelli L, Bowden R. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients. Bone Marrow Transplant 1999; 23:697-703.
    
    
33. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995; 21:1145-53.
    
    
34. Villanueva A, Arathoon EG, Gotuzzo E et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001:33, 1529-35
    
35. Arathoon EG, Gotuzzo E, Noriega LM et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46:451-7.
    
36. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. New Engl J Med 2002; 347:2020-9.
    
    
37. Maertens J, Raad I, Pettrikos G et al. Update of the multicenter noncomparative study of caspofungin in adults with invasive aspergillosis refractory or intolerant to other antifungal agents: analysis of 90 patients. Abstract M-868, 42nd ICAAC Abstracts, American Society for Microbiology, September 27-30, 2002 San Diego, CA, page 388.
    
    
38. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus Amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
    
    
39. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-71.
    
    
40. Ally R, Schurmann D, Kreisel W et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33:1447-54.
    
    
41. Meletiadis J, Mouton JW, Rodriguez-Tudela JL et al. In vitro interaction of terbinafine with itraconazole against clinical isolates of scedosporium prolificans. Antimicrob Agents Chemother 2000; 44:470-2.
    
    
42. Franzot SP, Casadevall A. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrobial Agents Chemother. 1997; 41:331-6.
    
43. Bartizal K, Gill CJ, Abruzzo GK et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-09991 (L-743,872). Antimicrob Agents Chemother. 1997; 41:2326-32
    
    
44. Aliff TB, Maslak PG, Jurcic JG et al. Refractory aspergillus pneumonia in patients with acute leukemia. Successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003;97:1025-32.